Grifols, S.A. (GRFS)

Market Cap	5.65B
Revenue (ttm)	6.45B
Net Income (ttm)	221.57M
Shares Out	863.37M
EPS (ttm)	0.33
PE Ratio	64.80
Forward PE	14.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	754,930
Open	6.64
Previous Close	6.58
Day's Range	6.46 - 6.64
52-Week Range	5.30 - 12.15
Beta	0.68
Analysts	Sell
Price Target	10.50 (+60.55%)
Earnings Date	Jul 28, 2022

About GRFS

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: May 17, 2006
• Employees: 26,314
• Stock Exchange: NASDAQ
• Ticker Symbol: GRFS

Financial Performance

In 2022, Grifols's revenue was 6.06 billion, an increase of 22.92% compared to the previous year's 4.93 billion. Earnings were 208.28 million, an increase of 10.36%.

Financial numbers in EUR

Analyst Forecast

According to 2 analysts, the average rating for GRFS stock is "Sell." The 12-month stock price forecast is $10.5, which is an increase of 60.55% from the latest price.

Price Target

$10.5

(60.55% upside)

Analyst Consensus: Sell